Table 1.
Baseline characteristics of participants. Values are numbers (percentages) unless stated otherwise
Characteristic
Placebo (n=215)
Galantamine 24 mg (n=220)
Galantamine 32 mg (n=218)
Demography
Men/women
83/132
81/139
80/138
Mean (SD) age (years)
72.7 (7.6)
71.9 (8.3)
72.1 (8.6)
Clinical
Mean (SD) weight (kg)
67.2 (12.1)
66.7 (12.8)
66.2 (13.4)
No (%) of smokers
193 (90)
200 (91)
199 (91)
Other active medical conditions
154 (72)
159 (72)
168 (77)
No (%) with apolipoprotein E4 allele
*
Homozygous
34 (18)
32 (17)
27 (15)
Heterozygous
83 (45)
97 (53)
95 (53)
Mean (SD) mini-mental state examination score
19.3 (3.5)
19.5 (3.4)
19.0 (3.8)
Mean (SD) Alzheimer's disease assessment scale score
24.7 (9.3)
25.4 (9.4)
26.2 (10.4)
Mean (SD) disability assessment in dementia score
66.6 (22.5)
69.9 (21.4)
69.6 (20.6)
Mean (SD) time since cognitive problem diagnosed (years)
3.5 (2.3)
3.6 (2.7)
3.7 (2.2)
Mean (SD) time since probable Alzheimer's disease diagnosed (years)
0.8 (1.0)
0.9 (1.2)
0.8 (1.0)
Brain imaging findings
Territorial infarctions
1 (0.5)
7 (3)
2 (1)
Lacunar infarctions
17 (8)
10 (5)
16 (7)
White matter lesions
0
0
2 (1)
Tumour
0
1 (0.5)
1 (0.5)
*
n=185 for placebo, n=184 for galantamine 24 mg, and n=179 for galantamine 32 mg.
11 item cognitive subscale.
Computed tomography or magnetic resonance imaging findings in past 12 months.
